Oncology_Logotype-site-1Oncology_Logotype-site-1Oncology_Logotype-site-1Oncology_Logotype-site-1
  • Main
  • Сlinical Trials
    • Completed phase I/IIa clinical trial
    • Case studies
    • Ex-US Clinical Trials
    • US clinical trials
  • Dogs & Cats
    • Comparative Medicine and Veterinary Research
  • Elenagen
    • Elenagen is a Plasmid (Circular DNA) Encoding Gene P62/SQSTM1
    • Elenagen Reduces/Reverts Tumor Grade
    • Elenagen Changes Tumor Microenvironment
    • Elenagen Downregulates Chronic Inflammation
    • Elenagen Enhances Anti-Tumoral Immune Response
  • IP
  • Publications
  • Investors
    • One-pager
    • Slide presentation
  • Team
    • Management Team
    • Scientific Advisory Board
    • Board of Directors
    • Careers
  • News
    • Company news
    • In the news
  • Legal
CureLab Oncology adds Hong Kong to expanding scope of patent protection
March 15, 2021
CureLab Oncology Granted US Patent for Therapeutic Use of its Lead Product in ALS, Alzheimer’s, Huntington’s, and Parkinson’s Diseases
July 20, 2021
June 30, 2021

CureLab Oncology Submits Patent for COVID Therapeutic Ahead of Phase I Clinical Trials

CureLab Oncology intends to determine whether its Elenagen DNA vaccine can be used to reduce severity, mortality and life-threatening post-COVID complications.
CureLab-WIPO-composite

BOSTON – June 30, 2021: CureLab Oncology, a clinical-stage pre-IPO biotech company, has filed an International Patent Cooperation Treaty (PCT) application to cover a new anti-COVID therapeutic application of its lead product, Elenagen™, ahead of planned ex-US clinical trials. The PCT application continues CureLab’s previously submitted US provisional patent application.

Elenagen is CureLab Oncology’s experimental DNA product that so far has demonstrated exceptional safety in cancer patients and anti-inflammatory capabilities in animal models. The combination of these two factors justify anti-COVID clinical trials because both the severity of COVID and the risk of post-COVID complications are partially rooted in systemic chronic toxicity.

“So far, we received the most encouraging therapeutic data with inflammatory cancers like triple-negative breast cancer and platinum-resistant ovarian cancer,” said Alex Shneider, Ph.D., CEO of CureLab Oncology. “We cannot make predictions, but we hope that similar clinical benefits will be observed in high-risk COVID patients because all high-risk comorbidities like diabetes or hypertension are related to chronic inflammation. Also, inflammation is associated with post-COVID myocarditis and other complications prevalent in young patients who have otherwise experienced mild COVID symptoms.”

For patients who have contracted COVID, CureLab Oncology intends to determine how Elenagen can be used to reduce mortality and life-threatening complications, and to shorten time to recovery. CureLab will also test Elenagen with patients who have recovered from COVID and are no longer virus-positive but are now suffering from post-COVID complications (long COVID).

About Elenagen

CureLab’s lead investigational compound is code-named Elenagen. It is a DNA vaccine that consists of a circular piece of DNA called a plasmid that includes a gene for a human protein called p62/SQSTM1. In animal studies and Phase I/II human trials conducted ex-US, Elenagen has shown promise in reversing tumor grade, changing the tumor microenvironment, and enhancing the anti-cancer effects of chemotherapy. Experimental results indicate a mitigation of chronic inflammation and stimulation of an immune response to the tumor.

About CureLab Oncology

CureLab Oncology Inc. is a clinical-stage immuno-oncology biotech company headquartered in the greater Boston area. CureLab is dedicated to advancing new and safer therapeutics for solid tumors and other oncology and inflammatory indications. To learn more, visit curelaboncology.com.

Media contact:

Tim Cox, ZingPR, tim@zingpr.com

Share

Related posts

November 5, 2022

Biotech Internship Opportunity! FDA/USDA liaison


Read more

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Corporate Mission

CureLab Oncology is a biotechnology company that is developing new anti-cancer biologics.
CureLab Oncology is committed to creating a family of revolutionary
therapies for oncology patients in order to help prolong their lives.

Our Lead Product

Our lead product, Elenagen, is a plasmid (supercoiled circular DNA) encoding gene p62/SQSTM1. Elenagen reverses tumor grade, changes tumor microenvironment, enhances the anti-cancer effects of other therapies (e.g. chemotherapy), mitigates chronic inflammation, and stimulates an immune attack on the tumor.

Clinical Trials

  • The CureLab Oncology team has completed its international Phase I/IIa Clinical Trials of Elenagen.
  • The vaccine demonstrated a high degree of safety as well as clinical benefits in a number of patients.
  • We are now preparing Phase II Clinical Trials within the US.

Contact us

E-mail:

info@curelab.com,

Call us:

1-609-841-1201

177 HUNTINGTON
AVE FL 17
BOSTON MA 02115-3156
© 2020 CureLab Oncology.